Citius Pharmaceuticals Reports Remarkable After-Hours Trading Surge
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) saw its shares rise by 22.12% in after-hours trading, reaching $1.27 on Tuesday. This notable increase followed the company's recent business updates for fiscal year 2025, along with the commercial launch of its leading oncology treatment, LYMPHIR.
Launch of LYMPHIR and Its Significance
The biopharmaceutical company, based in New Jersey, officially introduced LYMPHIR (denileukin diftitox-cxdl), a recombinant engineered fusion protein. This therapy was made available through its subsidiary, Citius Oncology, making it the first new treatment for cutaneous T-cell lymphoma (CTCL) since 2018.
LYMPHIR has received approval from the Food and Drug Administration and is designed for adult patients battling relapsed or refractory Stage I-III CTCL who have undergone at least one prior systemic therapy. The launch has been hailed as a significant milestone by company leadership.
CEO's Commitment to Patients
Leonard Mazur, the Chairman and CEO of Citius Pharmaceuticals, expressed pride in achieving this milestone. He emphasized the company’s dedication to executing its strategies effectively and delivering meaningful treatments to patients who have limited options in their healthcare journeys.
Market Access and Infrastructure Development
In preparation for the rollout of LYMPHIR, Citius Pharmaceuticals secured a permanent Healthcare Common Procedure Coding System J-code (J9161) and garnered a Category 2A recommendation from the National Comprehensive Cancer Network. These accomplishments are crucial as they facilitate improved access for patients and healthcare providers.
The company's strategic agreements with three leading U.S. pharmaceutical wholesalers ensure that LYMPHIR will be readily available nationwide, with commercial supply estimated to last for about 18 months. The therapy is also actively marketed in 19 international markets through named patient programs, broadening its reach.
Exploring Financial Outcomes for Fiscal Year 2025
As part of the most recent updates, Citius Pharmaceuticals reported a net loss of $39.7 million, translating to $3.38 per share, which is a slight improvement from a net loss of $40.2 million, or $5.97 per share, reported in the previous fiscal year. The company successfully raised approximately $61 million through capital initiatives, although it held $4.3 million in cash and cash equivalents by the end of September.
Research and development expenses saw a decline to $9.2 million from the prior year’s $11.9 million. In contrast, key general and administrative expenses increased slightly to $18.5 million from $18.2 million. Notably, the company did not report any revenue during fiscal 2025, highlighting ongoing investments without immediate returns.
Trading Metrics and Market Performance
The Citius Pharmaceuticals stock is currently exhibiting a Relative Strength Index (RSI) of 42.25. With a market capitalization of $16.57 million, the stock has witnessed a fluctuation between a 52-week high of $5.95 and a low of $0.65. Over the past year, the share price has dropped by 66.77%, underscoring the persistent challenges the company faces in the competitive healthcare market.
As the stock closed at $1.04 on Tuesday—a decline of 0.95%—it is positioned about 7.4% above its lowest point in the last year. This positioning might prompt traders to proceed with caution, given the potential for volatility in the near future.
Frequently Asked Questions
What drove the recent surge in Citius Pharmaceuticals' stock?
The stock surged due to a business update and the commercial launch of its oncology therapy, LYMPHIR.
What is LYMPHIR, and who is it for?
LYMPHIR is a novel therapy approved for adult patients with relapsed or refractory Stage I-III CTCL, aiming to provide new treatment options.
How did Citius Pharmaceuticals perform financially this fiscal year?
The company reported a net loss of $39.7 million, with no revenue for the fiscal year 2025, indicating ongoing investments in development.
What are the trading metrics of CTXR stock?
The stock has an RSI of 42.25, with a market cap of $16.57 million and a significant drop of 66.77% over the past year.
What future plans does Citius Pharmaceuticals have?
The company is focused on continuing its commitments to bring impactful treatments to patients and expanding market access for LYMPHIR.
